Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EryDex in Steroid-dependent Crohn's Disease
NCT01277289Phase 3Terminated
- Sponsor
- IRulya Therapeutics
- Start
- Jun 2009
- Primary completion
- Dec 2011
- Modality
- Nanoparticles, Small Molecules, Device-based Delivery
- Countries
- 3
01
Overview
A Phase 3 trial of EryDex in Crohn's disease, sponsored by IRulya Therapeutics. Started Jun 2009; status: terminated.
02
Drugs
EryDex
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01277289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01277289.